For the quarter ending 2026-03-31, JANX had -$506K decrease in cash & cash equivalents over the period. -$12,610K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -24,361 | -31,946 | -24,313 | -57,366 |
| Depreciation | 469 | 468 | 501 | 1,060 |
| Stock-based compensation | 9,269 | 9,515 | 9,044 | 21,662 |
| Accretion of discounts on investments, net | 2,624 | 3,524 | 4,623 | 9,427 |
| Accounts receivable | 35,000 | - | - | 0 |
| Prepaid expenses and other current assets | 1,343 | 227 | -449 | 1,049 |
| Other long-term assets | 1,336 | -19 | -66 | -191 |
| Accounts payable | -1,612 | 1,669 | -168 | -524 |
| Accrued expenses | -2,030 | -4,516 | 6,179 | 4,627 |
| Deferred revenue | 46,267 | 0 | 0 | 0 |
| Operating lease right-of-use assets and liabilities, net | 36 | 0 | -9 | 11 |
| Net cash used in operating activities | -12,337 | -28,542 | -12,856 | -40,837 |
| Purchases of property and equipment | 273 | 106 | 93 | 844 |
| Purchases of short-term investments | 112,751 | 123,277 | 117,969 | 463,976 |
| Maturities of short-term investments | 121,310 | 152,926 | 126,368 | 125,990 |
| Net cash provided by (used in) investing activities | 8,286 | 29,543 | 8,306 | -338,830 |
| Proceeds from exercise of common stock options and employee stock purchase plan | - | 2,944 | 493 | 1,855 |
| Proceeds from exercise of common stock options | 3,545 | - | - | - |
| Proceeds from the issuance of common stock and pre-funded common stock warrants, net of issuance costs | - | 0 | 0 | -347 |
| Payments of issuance costs | 0 | - | - | - |
| Net cash provided by financing activities | 3,545 | 2,944 | 493 | 1,508 |
| Net decrease in cash, cash equivalents and restricted cash | -506 | 3,945 | -4,057 | -378,159 |
| Cash, cash equivalents and restricted cash - beginning of year | 53,150 | 49,205 | 431,421 | - |
| Cash, cash equivalents and restricted cash - end of period | 52,644 | 53,150 | 49,205 | - |
Janux Therapeutics, Inc. (JANX)
Janux Therapeutics, Inc. (JANX)